Royal Bank Of Canada Leap Therapeutics, Inc. Transaction History

Royal Bank Of Canada

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$0.42 - $0.78 $77 - $144	-185 Reduced 88.94%	23 $0
Q3 2022 Nov 14, 2022	SELL	$0.92 - $1.75 $728 - $1,386	-792 Reduced 79.2%	208 $0
Q2 2022 Aug 15, 2022	SELL	$0.96 - $1.91 $5 - $11	-6 Reduced 0.6%	1,000 $1,000
Q1 2022 May 16, 2022	BUY	$1.6 - $3.35 $1,609 - $3,370	1,006 New	1,006 $2,000
Q3 2021 Nov 15, 2021	SELL	$1.35 - $4.01 $2,725 - $8,096	-2,019 Closed	0 $0

Q2 2021 Aug 16, 2021	BUY	$1.48 - $1.92 $2,988 - $3,876	2,019 New	2,019 $3,000

265K

Ticker LPTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 99,021,400
Market Cap $198M
Description
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate can...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.